FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:2002-2004 June 24, 1999 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Turrisi, A. T.

To the Editor: In their study of the treatment of small-cell lung cancer with radiotherapy and concurrent cisplatin and etoposide, Turrisi et al. (Jan. 28 issue)¹ concluded, "Twice-daily treatment significantly improved survival as compared with concurrent once-daily radiotherapy." Some readers might take this to mean that twice-daily fractionation was superior to once-daily treatment for such patients. Nothing could be further from the truth. What was demonstrated in this study is that twice-daily treatment at doses that were barely tolerable (grade 3 esophagitis developed in 27 percent of these patients) were slightly more effective than what we know to be inadequate . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Damoiseaux, R., van der Wouden, J. C., Bueving, H. (2005). Influenza Vaccination Effectiveness Is Not Proven in Younger Individuals at Risk. Arch Intern Med 165: 1921-1922 [Full Text]